Drug Class
Platinum compounds

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


Annotated Labels

  1. FDA Label for carboplatin
  2. FDA Label for cisplatin and TPMT
  3. FDA Label for oxaliplatin




PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for Platinum compounds

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA GSTM1 non-null N/A N/A N/A
No VIP available No VIP available VA GSTM1 null N/A N/A N/A
No VIP available No VIP available VA GSTT1 non-null N/A N/A N/A
No VIP available No VIP available VA GSTT1 null N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs10120688 NC_000009.11:g.22056499G>A, NC_000009.12:g.22056500G>A, NR_003529.3:n.1388+113G>A, NR_047532.1:n.1075+113G>A, NR_047533.1:n.644+7272G>A, NR_047534.1:n.644+7272G>A, NR_047535.1:n.780+113G>A, NR_047536.1:n.644+7272G>A, NR_047537.1:n.780+113G>A, NR_047538.1:n.644+7272G>A, NR_047539.1:n.1388+113G>A, NR_047540.1:n.780+113G>A, NR_047541.1:n.780+113G>A, NR_047542.1:n.780+113G>A, NR_047543.1:n.780+113G>A, NR_120536.1:n.644+7272G>A, rs60168433
G > A
SNP
No VIP available CA VA
rs1042927 NC_000011.10:g.4138699C>A, NC_000011.9:g.4159929C>A, NG_027992.2:g.49006C>A, NM_001033.3:c.*316C>A, NM_001033.4:c.*316C>A, NM_001318064.1:c.*316C>A, NM_001318065.1:c.*316C>A, XM_005253058.1:c.*316C>A, XM_005253059.1:c.*316C>A, XM_011520277.1:c.*316C>A, XM_011520278.1:c.*316C>A, XM_011520279.1:c.*316C>A, rs16930058, rs1735067, rs3168058, rs58834141
C > A
SNP
No VIP available No Clinical Annotations available VA
rs1045411 NC_000013.10:g.31033232C>T, NC_000013.11:g.30459095C>T, NM_001313892.1:c.*2262G>A, NM_001313893.1:c.*2262G>A, NM_002128.5:c.*2262G>A, rs17662679, rs3185290, rs74242030
C > T
SNP
No VIP available CA VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1047768 NC_000013.10:g.103504517T>C, NC_000013.11:g.102852167T>C, NG_007146.1:g.11344T>C, NM_000123.3:c.138T>C, NM_001204425.1:c.1500T>C, NP_000114.2:p.His46=, NP_001191354.1:p.His500=, XR_243039.1:n.564T>C, rs17260800, rs17845958, rs17858940, rs2227868, rs2266745, rs3187785, rs4150265
T > C
SNP
H46H
No VIP available CA VA
rs10510050 NC_000010.10:g.120626562A>G, NC_000010.11:g.118867050A>G, XR_946355.1:n.-742T>C, rs17665375, rs56784207
A > G
SNP
No VIP available CA VA
rs1052555 NC_000019.10:g.45352266G>A, NC_000019.9:g.45855524G>A, NG_007067.2:g.23322C>T, NM_000400.3:c.2133C>T, NP_000391.1:p.Asp711=, XM_005258639.1:c.2061C>T, XM_005258640.1:c.1899C>T, XM_005258641.1:c.1395C>T, XM_011526611.1:c.2055C>T, XP_005258696.1:p.Asp687=, XP_005258697.1:p.Asp633=, XP_005258698.1:p.Asp465=, XP_011524913.1:p.Asp685=, rs17285183, rs3170170, rs3916880
G > A
SNP
D711D
No VIP available No Clinical Annotations available VA
rs1061472 NC_000013.10:g.52524488T>C, NC_000013.11:g.51950352T>C, NG_008806.1:g.66143A>G, NM_000053.3:c.2495A>G, NM_001005918.2:c.2009A>G, NM_001243182.1:c.2162A>G, NP_000044.2:p.Lys832Arg, NP_001005918.1:p.Lys670Arg, NP_001230111.1:p.Lys721Arg, XM_005266423.1:c.2399A>G, XM_005266423.2:c.2399A>G, XM_005266424.1:c.2399A>G, XM_005266424.3:c.2399A>G, XM_005266425.1:c.2351A>G, XM_005266426.1:c.2495A>G, XM_005266427.1:c.2261A>G, XM_005266427.2:c.2261A>G, XM_005266428.1:c.2243A>G, XM_005266429.1:c.2495A>G, XM_005266430.1:c.2495A>G, XM_005266430.3:c.2495A>G, XM_005266431.1:c.2459A>G, XM_005266431.2:c.2459A>G, XM_005266432.1:c.2009A>G, XM_005266432.2:c.2009A>G, XM_005266433.1:c.1286-191A>G, XM_005266434.1:c.779A>G, XM_006719837.2:c.2399A>G, XM_006719838.1:c.311A>G, XM_006719839.1:c.311A>G, XM_011535117.1:c.2399A>G, XM_011535118.1:c.2495A>G, XM_011535119.1:c.2495A>G, XM_011535120.1:c.2081A>G, XM_011535121.1:c.2495A>G, XM_011535122.1:c.1163A>G, XP_005266480.1:p.Lys800Arg, XP_005266481.1:p.Lys800Arg, XP_005266482.1:p.Lys784Arg, XP_005266483.1:p.Lys832Arg, XP_005266484.1:p.Lys754Arg, XP_005266485.1:p.Lys748Arg, XP_005266486.1:p.Lys832Arg, XP_005266487.1:p.Lys832Arg, XP_005266488.1:p.Lys820Arg, XP_005266489.1:p.Lys670Arg, XP_005266491.1:p.Lys260Arg, XP_006719900.1:p.Lys800Arg, XP_006719901.1:p.Lys104Arg, XP_006719902.1:p.Lys104Arg, XP_011533419.1:p.Lys800Arg, XP_011533420.1:p.Lys832Arg, XP_011533421.1:p.Lys832Arg, XP_011533422.1:p.Lys694Arg, XP_011533423.1:p.Lys832Arg, XP_011533424.1:p.Lys388Arg, XR_245388.1:n.2714A>G, XR_941601.1:n.2714A>G, XR_941602.1:n.2714A>G, XR_941603.1:n.2714A>G, XR_941604.1:n.2714A>G, rs117058075, rs17435026, rs3202569, rs386514561, rs52815103, rs59677013
T > C
SNP
K832R
No VIP available No Clinical Annotations available VA
rs10787899 NC_000010.10:g.120798655G>A, NC_000010.11:g.119039143G>A, NM_003750.2:c.3527-704C>T, XM_005270259.1:c.3497-704C>T, XM_005270260.1:c.3425-704C>T, rs61307620
G > A
SNP
No VIP available CA VA
rs10878232 NC_000012.11:g.65522647T>G, NC_000012.12:g.65128867T>G
T > G
SNP
No VIP available No Clinical Annotations available VA
rs10886342 NC_000010.10:g.120690832G>A, NC_000010.11:g.118931320G>A, rs386515769, rs60264377
G > A
SNP
No VIP available No Clinical Annotations available VA
rs10895256 NC_000011.10:g.102107673T>G, NC_000011.9:g.101978404T>G, NG_029530.1:g.2213T>G, rs57332716
T > G
SNP
No VIP available CA VA
rs11030918 NC_000011.10:g.4094257T>C, NC_000011.9:g.4115487T>C, NG_016277.1:g.243555T>C, NG_027992.2:g.4564T>C, NM_001033.4:c.-756T>C, NM_001318064.1:c.-869T>C, XM_005253058.1:c.-756T>C, XM_005253059.1:c.-869T>C, XM_011520277.1:c.-869T>C, rs17210557, rs17554091
T > C
SNP
No VIP available No Clinical Annotations available VA
rs11198804 NC_000010.10:g.120909785C>T, NC_000010.11:g.119150273C>T, NG_033895.1:g.20420G>A, NM_213649.1:c.733-2413G>A, NR_110305.1:n.751-2413G>A, XM_005269525.1:c.706-2413G>A, XM_005269525.3:c.706-2413G>A, XM_005269526.1:c.385-2413G>A, XM_005269527.1:c.385-2413G>A, XM_011539282.1:c.385-2413G>A, XR_246070.1:n.795-2413G>A, XR_246071.1:n.768-2413G>A, XR_945603.1:n.795-2413G>A, rs56640007
C > T
SNP
No VIP available CA VA
rs1127687 NC_000010.10:g.115490109G>A, NC_000010.11:g.113730350G>A, NM_001227.4:c.*810G>A, NM_001267056.1:c.*810G>A, NM_001267057.1:c.*810G>A, NM_001267058.1:c.*810G>A, NM_033338.5:c.*810G>A, NM_033339.4:c.*810G>A, NM_033340.3:c.*926G>A, XM_006718017.2:c.*810G>A, XM_006718018.1:c.*810G>A, XM_011540259.1:c.*810G>A, XM_011540260.1:c.*810G>A, rs3183905, rs56449372
G > A
SNP
No VIP available CA VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available No Clinical Annotations available VA
rs1138272 NC_000011.10:g.67586108C>T, NC_000011.9:g.67353579C>T, NG_012075.1:g.7514C>T, NM_000852.3:c.341C>T, NP_000843.1:p.Ala114Val, XM_005273958.1:c.338C>T, XP_005274015.1:p.Ala113Val, rs11553894, rs17434783, rs1799811, rs1804665, rs3202011, rs4134657, rs52800258, rs61323549
C > T
SNP
A114V
No VIP available CA VA
rs1143623 NC_000002.11:g.113595829C>G, NC_000002.12:g.112838252C>G, NG_008851.1:g.3528G>C, NM_000576.2:c.-1560G>C, rs17042471, rs59448529
C > G
SNP
No VIP available CA VA
rs11615 NC_000019.10:g.45420395A>G, NC_000019.9:g.45923653A>G, NG_015839.2:g.63434T>C, NM_001166049.1:c.354T>C, NM_001983.3:c.354T>C, NM_202001.2:c.354T>C, NP_001159521.1:p.Asn118=, NP_001974.1:p.Asn118=, NP_973730.1:p.Asn118=, XM_005258634.1:c.354T>C, XM_005258635.1:c.354T>C, XM_005258635.2:c.354T>C, XM_005258636.1:c.354T>C, XM_005258636.3:c.354T>C, XM_005258637.1:c.354T>C, XM_005258638.1:c.138T>C, XM_011526610.1:c.354T>C, XP_005258691.1:p.Asn118=, XP_005258692.1:p.Asn118=, XP_005258693.1:p.Asn118=, XP_005258694.1:p.Asn118=, XP_005258695.1:p.Asn46=, XP_011524912.1:p.Asn118=, rs1130005, rs17285882, rs17359303, rs17845191, rs17858003, rs17859564, rs2228629, rs3177700, rs3188446, rs3752251, rs59923575
A > G
SNP
N118N
No VIP available No Clinical Annotations available VA
rs116907618 NC_000014.8:g.101324135G>C, NC_000014.9:g.100857798G>C, NG_016853.1:g.36691G>C, NR_002766.2:n.1260-2893G>C, NR_003530.2:n.1510-2893G>C, NR_003531.3:n.1377-2893G>C, NR_033358.1:n.1390-2893G>C, NR_033359.1:n.1369-2893G>C, NR_033360.1:n.1276-2893G>C, NR_046464.1:n.1324-2893G>C, NR_046465.2:n.1298-2893G>C, NR_046466.1:n.1146-2893G>C, NR_046467.1:n.1428-2893G>C, NR_046468.2:n.1390-2893G>C, NR_046469.1:n.1290-2893G>C, NR_046470.2:n.1420-2893G>C, NR_046471.1:n.1184-2893G>C, NR_046472.1:n.1314-2893G>C
G > C
SNP
No VIP available CA VA
rs11868547 NC_000017.10:g.63523603G>C, NC_000017.11:g.65527485G>C, NG_012142.1:g.39138C>G, rs56601766
G > C
SNP
No VIP available CA VA
rs12415607 NC_000010.10:g.115438204C>A, NC_000010.11:g.113678445C>A, NM_001227.4:c.-1534C>A, NM_001267056.1:c.-905C>A, NM_001267057.1:c.-1310C>A, NM_033338.5:c.-1542C>A, NM_033339.4:c.-1608C>A, NM_033340.3:c.-905C>A, XM_006718018.1:c.-912C>A, rs34414451, rs56491430, rs60647096
C > A
SNP
No VIP available CA VA
rs12621220
C > T
SNP
No VIP available CA VA
rs12806698 NC_000011.10:g.4094744C>A, NC_000011.9:g.4115974C>A, NG_016277.1:g.244042C>A, NG_027992.2:g.5051C>A, NM_001033.3:c.-269C>A, NM_001033.4:c.-269C>A, NM_001318064.1:c.-382C>A, XM_005253058.1:c.-269C>A, XM_005253059.1:c.-382C>A, XM_011520277.1:c.-382C>A, rs17554111
C > A
SNP
No VIP available CA VA
rs12819505 NC_000012.11:g.1756665A>G, NC_000012.12:g.1647499A>G, NM_030775.2:c.*1247A>G, NM_032642.2:c.*1247A>G, XM_005253792.1:c.*1247A>G, XM_005253793.1:c.*1247A>G, XM_005253794.1:c.*1247A>G, XM_011521026.1:c.*1247A>G
A > G
SNP
No VIP available CA VA
rs13181 NC_000019.10:g.45351661T>G, NC_000019.9:g.45854919T>G, NG_007067.2:g.23927A>C, NM_000400.3:c.2251A>C, NM_177417.2:c.*304T>G, NP_000391.1:p.Lys751Gln, XM_005258536.1:c.*128T>G, XM_005258536.3:c.*128T>G, XM_005258537.1:c.*128T>G, XM_005258538.1:c.*304T>G, XM_005258539.1:c.*304T>G, XM_005258639.1:c.2179A>C, XM_005258640.1:c.2017A>C, XM_005258641.1:c.1513A>C, XM_011526611.1:c.2173A>C, XP_005258696.1:p.Lys727Gln, XP_005258697.1:p.Lys673Gln, XP_005258698.1:p.Lys505Gln, XP_011524913.1:p.Lys725Gln, rs1052559, rs17285142, rs17355147, rs17359310, rs3170171, rs3859422, rs60606175
T > G
SNP
K751Q
No VIP available No Clinical Annotations available VA
rs1333049 NC_000009.11:g.22125503G>C, NC_000009.12:g.22125504G>C, rs17761501, rs58844516, rs59077428
G > C
SNP
No VIP available CA VA
rs1409314 NC_000010.10:g.120615752A>G, NC_000010.11:g.118856240A>G, XR_946355.1:n.122+9947T>C, rs56620836, rs59117276
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1412125 NC_000013.10:g.31041595C>T, NC_000013.11:g.30467458C>T, NM_001313893.1:c.-14-3764G>A, NM_002128.5:c.-1677G>A, XM_005266364.1:c.-14-3764G>A, XM_005266367.1:c.-14-3764G>A, XM_005266368.1:c.-1677G>A, XM_011535056.1:c.-1677G>A, XR_941568.1:n.-1521G>A, rs56766653
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1690924
T > C
SNP
No VIP available No Clinical Annotations available VA
rs16944 NC_000002.11:g.113594867A>G, NC_000002.12:g.112837290A>G, NG_008851.1:g.4490T>C, NM_000576.2:c.-598T>C, XM_006712496.1:c.-1552T>C, rs3827762
A > G
SNP
No VIP available CA VA
rs1695 NC_000011.10:g.67585218A>G, NC_000011.9:g.67352689A>G, NG_012075.1:g.6624A>G, NM_000852.3:c.313A>G, NP_000843.1:p.Ile105Val, XM_005273958.1:c.313A>G, XP_005274015.1:p.Ile105Val, rs1138257, rs11553891, rs17353321, rs17856342, rs2230827, rs4609, rs56971933, rs947894
A > G
SNP
I105V
No VIP available CA VA
rs1799782 NC_000019.10:g.43553422G>A, NC_000019.9:g.44057574G>A, NG_033799.1:g.27157C>T, NM_006297.2:c.580C>T, NP_006288.2:p.Arg194Trp, rs11553655, rs2229674, rs3213359, rs3826914, rs386545546
G > A
SNP
R194W
No VIP available CA VA
rs1799793 NC_000019.10:g.45364001C>T, NC_000019.9:g.45867259C>T, NG_007067.2:g.11587G>A, NM_000400.3:c.934G>A, NM_001130867.1:c.862G>A, NP_000391.1:p.Asp312Asn, NP_001124339.1:p.Asp288Asn, XM_005258639.1:c.862G>A, XM_005258640.1:c.700G>A, XM_005258641.1:c.196G>A, XM_005258642.1:c.934G>A, XM_011526611.1:c.856G>A, XP_005258696.1:p.Asp288Asn, XP_005258697.1:p.Asp234Asn, XP_005258698.1:p.Asp66Asn, XP_005258699.1:p.Asp312Asn, XP_011524913.1:p.Asp286Asn, XR_935763.1:n.981G>A, rs3916814, rs58989209
C > T
SNP
D312N
No VIP available CA VA
rs1799801 NC_000016.10:g.13948101T>C, NC_000016.9:g.14041958T>C, NG_011442.1:g.32945T>C, NM_005236.2:c.2505T>C, NP_005227.1:p.Ser835=, XM_011522424.1:c.2643T>C, XM_011522425.1:c.1962T>C, XM_011522426.1:c.1716T>C, XM_011522427.1:c.1155T>C, XP_011520726.1:p.Ser881=, XP_011520727.1:p.Ser654=, XP_011520728.1:p.Ser572=, XP_011520729.1:p.Ser385=, XR_243267.1:n.2511T>C, XR_932805.1:n.2664T>C
T > C
SNP
S835S
No VIP available CA No Variant Annotations available
rs1799983 NC_000007.13:g.150696111T>G, NC_000007.14:g.150999023T>G, NG_011992.1:g.12965T>G, NM_000603.4:c.894T>G, NM_001160109.1:c.894T>G, NM_001160110.1:c.894T>G, NM_001160111.1:c.894T>G, NP_000594.2:p.Asp298Glu, NP_001153581.1:p.Asp298Glu, NP_001153582.1:p.Asp298Glu, NP_001153583.1:p.Asp298Glu, XM_006716002.2:c.894T>G, XP_006716065.1:p.Asp298Glu, rs11266811, rs13238975, rs13305983, rs13308813, rs17173672, rs3730304, rs57135373
T > G
SNP
D298E
No VIP available CA No Variant Annotations available
rs1800566 NC_000016.10:g.69711242G>A, NC_000016.9:g.69745145G>A, NG_011504.1:g.20389C>T, NM_000903.2:c.559C>T, NM_001025433.1:c.457C>T, NM_001025434.1:c.445C>T, NM_001286137.1:c.343C>T, NP_000894.1:p.Pro187Ser, NP_001020604.1:p.Pro153Ser, NP_001020605.1:p.Pro149Ser, NP_001273066.1:p.Pro115Ser, XM_005255830.1:c.343C>T, XP_005255887.1:p.Pro115Ser, rs4134727, rs4149351, rs57135274
G > A
SNP
P187S
No VIP available CA VA
rs1800975 NC_000009.11:g.100459578T>C, NC_000009.12:g.97697296T>C, NG_011642.1:g.5114A>G, NM_000380.3:c.-4A>G, NR_027302.1:n.114A>G, XM_006717278.1:c.-4A>G, XM_011518988.1:c.-4A>G, XR_929839.1:n.108A>G, rs13301768, rs16923638, rs3176632, rs58796599
T > -
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1859168 NC_000007.13:g.27242359A>C, NC_000007.14:g.27202740A>C, NG_008181.1:g.2367T>G, NR_037843.3:n.2117+102A>C, XR_242057.1:n.1250+953A>C, rs60390513, rs60490133
A > C
SNP
No VIP available No Clinical Annotations available VA
rs1899663 NC_000012.11:g.54360994C>A, NC_000012.12:g.53967210C>A, NR_003716.3:n.266+59G>T, NR_047517.1:n.325+59G>T, NR_047518.1:n.299-833G>T
C > A
SNP
No VIP available CA VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available No Clinical Annotations available VA
rs2071554 NC_000006.11:g.32784676C>T, NC_000006.12:g.32816899C>T, NG_009793.3:g.26872G>A, NG_012008.1:g.5150G>A, NM_002120.3:c.53G>A, NP_002111.1:p.Arg18Gln, NT_113891.2:g.4229206C>T, NT_113891.3:g.4229100C>T, NT_167244.1:g.4071839C>T, NT_167244.2:g.4121923C>T, NT_167245.1:g.4066202C>T, NT_167245.2:g.4060617C>T, NT_167247.1:g.4121577C>T, NT_167247.2:g.4115992C>T, NT_167249.1:g.4215609C>T, NT_167249.2:g.4216311C>T, rs115120730, rs117515083, rs143214015, rs17883529, rs45613631, rs52833026, rs60828729
C > T
SNP
R18Q
No VIP available No Clinical Annotations available VA
rs2072671 NC_000001.10:g.20915701A>C, NC_000001.11:g.20589208A>C, NM_001785.2:c.79A>C, NP_001776.1:p.Lys27Gln, rs57221291
A > C
SNP
K27Q
No VIP available No Clinical Annotations available VA
rs2107425 NC_000011.10:g.1999845C>T, NC_000011.9:g.2021075C>T, NG_016165.1:g.2991G>A, NR_002196.2:n.-1970G>A, NR_131223.1:n.-1970G>A, NR_131224.1:n.249+1373G>A, XM_011520273.1:c.498-11696C>T, XM_011520274.1:c.492-11696C>T, XM_011520275.1:c.498-11696C>T, rs57759891
C > T
SNP
No VIP available CA VA
rs2227310 NC_000010.10:g.115489152C>G, NC_000010.11:g.113729393C>G, NM_001227.4:c.765C>G, NM_001267056.1:c.765C>G, NM_001267057.1:c.1020C>G, NM_001267058.1:c.690C>G, NM_033338.5:c.864C>G, NM_033339.4:c.765C>G, NM_033340.3:c.731C>G, NP_001218.1:p.Asp255Glu, NP_001253985.1:p.Asp255Glu, NP_001253986.1:p.Asp340Glu, NP_001253987.1:p.Asp230Glu, NP_203124.1:p.Asp288Glu, NP_203125.1:p.Asp255Glu, NP_203126.1:p.Thr244Ser, XM_006718017.2:c.807C>G, XM_006718018.1:c.789C>G, XM_011540259.1:c.864C>G, XM_011540260.1:c.666C>G, XP_006718080.1:p.Asp269Glu, XP_006718081.1:p.Asp263Glu, XP_011538561.1:p.Asp288Glu, XP_011538562.1:p.Asp222Glu, rs56575824, rs58736298, rs58910029
C > G
SNP
D255E/S
No VIP available No Clinical Annotations available VA
rs2234767 NC_000010.10:g.90749256G>A, NC_000010.11:g.88989499G>A, NG_009089.2:g.3969G>A, NG_011541.1:g.6892C>T, NM_000043.4:c.-1378G>A, NM_001141945.1:c.-24+1440C>T, NM_152871.2:c.-1378G>A, NM_152872.2:c.-1378G>A, NR_028033.2:n.-1032G>A, NR_028034.2:n.-1032G>A, NR_028035.2:n.-1032G>A, NR_028036.2:n.-1032G>A, XM_006717819.2:c.31G>A, XM_011539764.1:c.112G>A, XM_011539765.1:c.112G>A, XM_011539766.1:c.31G>A, XM_011539767.1:c.-1639G>A, XM_011540016.1:c.-24+1523C>T, XP_006717882.1:p.Ala11Thr, XP_011538066.1:p.Ala38Thr, XP_011538067.1:p.Ala38Thr, XP_011538068.1:p.Ala11Thr, XR_945732.1:n.127G>A, XR_945733.1:n.127G>A, rs3758482
G > A
G > T
SNP
No VIP available No Clinical Annotations available VA
rs2249825 NC_000013.10:g.31037903G>C, NC_000013.11:g.30463766G>C, NM_001313892.1:c.-14-72C>G, NM_001313893.1:c.-14-72C>G, NM_002128.5:c.-14-72C>G, XM_005266363.1:c.-14-72C>G, XM_005266364.1:c.-14-72C>G, XM_005266365.1:c.-14-72C>G, XM_005266366.1:c.-14-72C>G, XM_005266367.1:c.-14-72C>G, XM_005266368.1:c.-14-72C>G, XM_011535055.1:c.-14-72C>G, XM_011535056.1:c.-14-72C>G, XR_941568.1:n.143-72C>G, rs17662811, rs60468656
G > A
G > C
SNP
No VIP available CA VA
rs2269577 NC_000022.10:g.29196757G>C, NC_000022.11:g.28800769G>C, NG_012266.1:g.4804C>G, NM_001079539.1:c.-245C>G, NM_005080.3:c.-245C>G, XM_011530435.1:c.-194+32G>C, XM_011530436.1:c.-262+32G>C, rs61323997
G > C
SNP
No VIP available No Clinical Annotations available VA
rs2275112 NC_000010.10:g.120917616G>A, NC_000010.11:g.119158104G>A, NG_033895.1:g.12589C>T, NM_213649.1:c.361-42C>T, NR_110305.1:n.379-42C>T, XM_005269525.1:c.334-42C>T, XM_005269525.3:c.334-42C>T, XM_005269526.1:c.13-42C>T, XM_005269527.1:c.13-42C>T, XM_011539282.1:c.13-42C>T, XR_246070.1:n.423-42C>T, XR_246071.1:n.396-42C>T, XR_945603.1:n.423-42C>T
G > A
SNP
No VIP available No Clinical Annotations available VA
rs238406 NC_000019.10:g.45365051T>G, NC_000019.9:g.45868309T>G, NG_007067.2:g.10537A>C, NM_000400.3:c.468A>C, NM_001130867.1:c.396A>C, NP_000391.1:p.Arg156=, NP_001124339.1:p.Arg132=, XM_005258639.1:c.396A>C, XM_005258640.1:c.361-504A>C, XM_005258641.1:c.-271A>C, XM_005258642.1:c.468A>C, XM_011526611.1:c.390A>C, XP_005258696.1:p.Arg132=, XP_005258699.1:p.Arg156=, XP_011524913.1:p.Arg130=, XR_935763.1:n.515A>C, rs11543157, rs17587147, rs3859425, rs59387636
T > G
SNP
R156R
No VIP available CA VA
rs25487 NC_000019.10:g.43551574T>C, NC_000019.9:g.44055726T>C, NG_033799.1:g.29005A>G, NM_006297.2:c.1196A>G, NP_006288.2:p.Gln399Arg, rs11553658, rs17435395, rs3817410, rs386493716, rs57378728
T > C
SNP
Q399R
No VIP available CA VA
rs2839698 NC_000011.10:g.1997623G>A, NC_000011.9:g.2018853G>A, NG_016165.1:g.5213C>T, NG_045220.1:g.10216G>A, NR_002196.2:n.253C>T, NR_030533.1:n.-792C>T, NR_131223.1:n.253C>T, NR_131224.1:n.250-1202C>T, XM_011520273.1:c.498-13918G>A, XM_011520274.1:c.492-13918G>A, XM_011520275.1:c.498-13918G>A, rs52828411
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2900420 NC_000012.11:g.10521794G>A, NC_000012.12:g.10369195G>A, NR_120430.1:n.266-4840G>A, XR_242912.1:n.266-4840G>A, rs201778694, rs4463923, rs61266878, rs76442040
G > A
SNP
No VIP available CA VA
rs3212986 NC_000019.10:g.45409478C>A, NC_000019.9:g.45912736C>A, NG_015839.2:g.74351G>T, NM_001166049.1:c.*197G>T, NM_001297590.1:c.1516C>A, NM_001983.3:c.*197G>T, NM_012099.1:c.1510C>A, NP_001284519.1:p.Gln506Lys, NP_036231.1:p.Gln504Lys, XM_005258425.1:c.1516C>A, XM_005258638.1:c.*197G>T, XP_005258482.1:p.Gln506Lys, rs386580934, rs60333438
C > A
C > T
SNP
Q506K
No VIP available CA VA
rs3213239 NC_000019.10:g.43576907_43576908insGGCC, NC_000019.9:g.44081059_44081060insGGCC, NG_033799.1:g.3671_3672insGGCC, NM_001193621.1:c.-18_-17insGGCC, NM_006297.2:c.-1450_-1449insGGCC, XM_011526970.1:c.-213_-212insGGCC, rs146254820
- > GGCC
indel
No VIP available CA VA
rs3738948 NC_000002.11:g.128018063A>G, NC_000002.12:g.127260487A>G, NG_007454.1:g.38690T>C, NM_000122.1:c.2064+741T>C, NM_001303416.1:c.1872+741T>C, NM_001303418.1:c.1872+741T>C, XM_005263618.1:c.1872+741T>C, XM_005263619.1:c.1872+741T>C, XM_011510794.1:c.2082+741T>C, XM_011510795.1:c.1626+741T>C, rs57713975
A > G
SNP
No VIP available No Clinical Annotations available VA
rs3807598 NC_000007.13:g.27240482C>G, NC_000007.14:g.27200863C>G, NG_008181.1:g.4244G>C, NM_000522.4:c.-786G>C, NR_037843.3:n.342C>G, XM_011515344.1:c.-786G>C, XR_242057.1:n.326C>G, rs10332585, rs17437587, rs52814862
C > G
SNP
No VIP available CA VA
rs430397 NC_000009.11:g.128001119C>T, NC_000009.12:g.125238840C>T, NG_027761.1:g.7548G>A, NM_005347.4:c.997-13G>A, rs11567635, rs35719250, rs3765559, rs52822178, rs60157411
C > T
SNP
No VIP available CA VA
rs4353229 NC_000010.10:g.115489589T>C, NC_000010.11:g.113729830T>C, NM_001227.4:c.*290T>C, NM_001267056.1:c.*290T>C, NM_001267057.1:c.*290T>C, NM_001267058.1:c.*290T>C, NM_033338.5:c.*290T>C, NM_033339.4:c.*290T>C, NM_033340.3:c.*406T>C, XM_006718017.2:c.*290T>C, XM_006718018.1:c.*290T>C, XM_011540259.1:c.*290T>C, XM_011540260.1:c.*290T>C, rs57355355
T > C
SNP
No VIP available CA VA
rs4413407 NC_000004.11:g.105393361A>G, NC_000004.12:g.104472204A>G, NM_025212.3:c.*118T>C, NR_132741.1:n.440T>C, XM_011532284.1:c.*118T>C
A > -
A > G
SNP
No VIP available CA VA
rs4541111 NC_000017.10:g.63534538C>A, NC_000017.11:g.65538420C>A, NG_012142.1:g.28203G>T, NM_004655.3:c.1060-77G>T, XM_005257716.1:c.1060-77G>T, XM_005257717.1:c.1060-77G>T, XM_005257718.1:c.1060-77G>T, XM_005257719.1:c.1060-77G>T, XM_011525319.1:c.1060-77G>T, XM_011525320.1:c.1060-77G>T, XM_011525321.1:c.1060-77G>T, XM_011525322.1:c.1060-77G>T, rs59628788
C > A
SNP
No VIP available CA VA
rs4752219 NC_000010.10:g.120615561C>T, NC_000010.11:g.118856049C>T, XR_946355.1:n.122+10138G>A, rs56609528, rs60729048
C > T
SNP
No VIP available CA VA
rs4752220 NC_000010.10:g.120615609A>G, NC_000010.11:g.118856097A>G, XR_946355.1:n.122+10090T>C, rs60249979
A > G
SNP
No VIP available No Clinical Annotations available VA
rs4752269 NC_000010.10:g.121037952C>T, NC_000010.11:g.119278440C>T, NM_005308.2:c.53-48076C>T, XM_005269707.1:c.53-48076C>T, XM_005269708.1:c.52+70471C>T, rs17606964, rs57284838
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4759314 NC_000012.11:g.54361835G>A, NC_000012.12:g.53968051G>A, NR_003716.3:n.140+566C>T, NR_047517.1:n.199+566C>T, NR_047518.1:n.298+566C>T, rs58946394
G > A
SNP
No VIP available CA VA
rs50872
A > G
SNP
No VIP available No Clinical Annotations available VA
rs5883064 NC_000007.13:g.27241879_27241880delCT, NC_000007.14:g.27202260_27202261delCT, NG_008181.1:g.2846_2847delAG, NR_037843.3:n.1739_1740delCT, XM_011515344.1:c.-2184_-2183del, XR_242057.1:n.1250+473_1250+474delCT, rs10585733, rs144082126, rs146691291, rs148437096, rs33960115, rs35545353, rs376981414, rs57119633, rs5883065
CT > -
indel
No VIP available CA VA
rs619586 NC_000011.10:g.65498698A>G, NC_000011.9:g.65266169A>G, NR_002819.3:n.937A>G, XR_247199.1:n.946A>G, XR_247200.1:n.884A>G, rs60317489
A > G
SNP
No VIP available No Clinical Annotations available VA
rs6832850 NC_000004.11:g.174249593A>T, NC_000004.12:g.173328442A>T, XR_939453.1:n.75+1178T>A, rs57214101
A > T
SNP
No VIP available CA VA
rs6983267 NC_000008.10:g.128413305G>T, NC_000008.11:g.127401060G>T, NR_109834.1:n.662G>T, NR_117100.1:n.1176+19769C>A, rs17467153, rs61163584
G > T
SNP
No VIP available CA VA
rs7091672 NC_000010.10:g.120596421T>C, NC_000010.11:g.118836909T>C, XR_946355.1:n.122+29278A>G, rs57277727
T > C
SNP
No VIP available CA VA
rs716274 NC_000011.10:g.103547430A>G, NC_000011.9:g.103418158A>G, rs56628356, rs57544138
A > G
SNP
No VIP available CA VA
rs7170924
G > T
SNP
No VIP available No Clinical Annotations available VA
rs763110 NC_000001.10:g.172627498C=, NC_000001.10:g.172627498C>T, NC_000001.11:g.172658358C=, NC_000001.11:g.172658358C>T, NG_007269.1:g.4314C=, NG_007269.1:g.4314C>T, NM_000639.2:c.-157-687C>T, NM_000639.2:c.-844C=, NM_001302746.1:c.-844C=, NM_001302746.1:c.-844C>T, rs59042607
C > T
SNP
No VIP available No Clinical Annotations available VA
rs7686909 NC_000004.11:g.174257693T>C, NC_000004.12:g.173336542T>C, XR_939464.1:n.77+1721T>C
T > C
SNP
No VIP available CA VA
rs7921977 NC_000010.10:g.115439569C>T, NC_000010.11:g.113679810C>T, NM_001227.4:c.-169C>T, NM_001267056.1:c.-1+461C>T, NM_001267057.1:c.56C>T, NM_033338.5:c.-177C>T, NM_033339.4:c.-243C>T, NM_033340.3:c.-1+461C>T, NP_001253986.1:p.Thr19Ile, XM_006718018.1:c.-8+461C>T, rs386479493, rs56841072
C > T
SNP
T19I
No VIP available CA VA
rs7958904 NC_000012.11:g.54357552C>G, NC_000012.12:g.53963768C>G, NR_003716.3:n.902G>C, NR_047517.1:n.908G>C, NR_047518.1:n.877G>C, rs59019285
C > G
SNP
No VIP available No Clinical Annotations available VA
rs7999812 NC_000013.10:g.52545495A>C, NC_000013.11:g.51971359A>C, NG_008806.1:g.45136T>G, NM_000053.3:c.1286-610T>G, NM_001005918.2:c.1286-610T>G, NM_001243182.1:c.953-610T>G, XM_005266423.1:c.1190-610T>G, XM_005266423.2:c.1190-610T>G, XM_005266424.1:c.1190-610T>G, XM_005266424.3:c.1190-610T>G, XM_005266425.1:c.1286-610T>G, XM_005266426.1:c.1286-610T>G, XM_005266427.1:c.1286-610T>G, XM_005266427.2:c.1286-610T>G, XM_005266428.1:c.1286-610T>G, XM_005266429.1:c.1286-610T>G, XM_005266430.1:c.1286-610T>G, XM_005266430.3:c.1286-610T>G, XM_005266431.1:c.1250-610T>G, XM_005266431.2:c.1250-610T>G, XM_005266432.1:c.1286-610T>G, XM_005266432.2:c.1286-610T>G, XM_005266433.1:c.1285+2576T>G, XM_005266434.1:c.-877T>G, XM_006719837.2:c.1190-610T>G, XM_011535117.1:c.1190-610T>G, XM_011535118.1:c.1286-610T>G, XM_011535119.1:c.1286-610T>G, XM_011535120.1:c.1286-610T>G, XM_011535121.1:c.1286-610T>G, XM_011535122.1:c.-47-610T>G, XR_245388.1:n.1505-610T>G, XR_941601.1:n.1505-610T>G, XR_941602.1:n.1505-610T>G, XR_941603.1:n.1505-610T>G, XR_941604.1:n.1505-610T>G
A > C
SNP
No VIP available CA VA
rs861539 NC_000014.8:g.104165753G>A, NC_000014.9:g.103699416G>A, NG_011516.1:g.21071C>T, NG_012307.1:g.75229G>A, NM_001100118.1:c.722C>T, NM_001100119.1:c.722C>T, NM_001130107.1:c.1782-1239G>A, NM_005432.3:c.722C>T, NM_182923.3:c.1651-1239G>A, NP_001093588.1:p.Thr241Met, NP_001093589.1:p.Thr241Met, NP_005423.1:p.Thr241Met, XM_005267599.1:c.1924-1239G>A, XM_005267600.1:c.*17-1239G>A, XM_005267602.1:c.1897-1239G>A, XM_005267603.1:c.*17-1239G>A, XM_005267604.1:c.1857-1239G>A, XM_005267605.1:c.1849-1239G>A, XM_005267606.1:c.*17-1239G>A, XM_005267607.1:c.1830-1239G>A, XM_005267608.1:c.1825-1239G>A, XM_005267609.1:c.1822-1239G>A, XM_005267610.1:c.*46-1239G>A, XM_005267612.1:c.*17-1239G>A, XM_005267613.1:c.1758-1239G>A, XM_005267614.1:c.1755-1239G>A, XM_005267615.1:c.1726-1239G>A, XM_005267616.1:c.*17-1239G>A, XM_005267617.1:c.1699-1239G>A, XM_005267618.1:c.*17-1239G>A, XM_005267624.1:c.1624-1239G>A, XM_005268045.1:c.722C>T, XM_005268046.1:c.722C>T, XM_005268047.1:c.722C>T, XM_011537138.1:c.722C>T, XP_005268102.1:p.Thr241Met, XP_005268103.1:p.Thr241Met, XP_005268104.1:p.Thr241Met, XP_011535440.1:p.Thr241Met, rs1734804, rs17435402, rs17850783, rs3212111, rs56934996
G > A
SNP
T241M
No VIP available CA VA
rs9535826 NC_000013.10:g.52566126T>G, NC_000013.11:g.51991990T>G, NG_008806.1:g.24505A>C, NM_000053.3:c.52-16822A>C, NM_001005918.2:c.52-16822A>C, NM_001243182.1:c.52-16822A>C, XM_005266425.1:c.52-16822A>C, XM_005266426.1:c.52-16822A>C, XM_005266427.1:c.52-16822A>C, XM_005266427.2:c.52-16822A>C, XM_005266428.1:c.52-16822A>C, XM_005266429.1:c.52-16822A>C, XM_005266430.1:c.52-16822A>C, XM_005266430.3:c.52-16822A>C, XM_005266431.1:c.15+3324A>C, XM_005266431.2:c.15+3324A>C, XM_005266432.1:c.52-16822A>C, XM_005266432.2:c.52-16822A>C, XM_005266433.1:c.52-16822A>C, XM_011535117.1:c.-46+14518A>C, XM_011535118.1:c.52-16822A>C, XM_011535119.1:c.52-16822A>C, XM_011535120.1:c.52-16822A>C, XM_011535121.1:c.52-16822A>C, XR_245388.1:n.271-16822A>C, XR_941601.1:n.271-16822A>C, XR_941602.1:n.271-16822A>C, XR_941603.1:n.271-16822A>C, XR_941604.1:n.271-16822A>C, rs61446037
T > G
SNP
No VIP available CA VA
rs9535828 NC_000013.10:g.52573422G>A, NC_000013.11:g.51999286G>A, NG_008806.1:g.17209C>T, NM_000053.3:c.51+12001C>T, NM_001005918.2:c.51+12001C>T, NM_001243182.1:c.51+12001C>T, XM_005266425.1:c.51+12001C>T, XM_005266426.1:c.51+12001C>T, XM_005266427.1:c.51+12001C>T, XM_005266427.2:c.51+12001C>T, XM_005266428.1:c.51+12001C>T, XM_005266429.1:c.51+12001C>T, XM_005266430.1:c.51+12001C>T, XM_005266430.3:c.51+12001C>T, XM_005266432.1:c.51+12001C>T, XM_005266432.2:c.51+12001C>T, XM_005266433.1:c.51+12001C>T, XM_011535117.1:c.-46+7222C>T, XM_011535118.1:c.51+12001C>T, XM_011535119.1:c.51+12001C>T, XM_011535120.1:c.51+12001C>T, XM_011535121.1:c.51+12001C>T, XR_245388.1:n.270+12001C>T, XR_941601.1:n.270+12001C>T, XR_941602.1:n.270+12001C>T, XR_941603.1:n.270+12001C>T, XR_941604.1:n.270+12001C>T
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
Brand Mixture Names

PharmGKB Accession Id

PA164713176

Other Vocabularies

Drugs And Small Molecules

The following have been classified under this therapeutic category:

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Platinum Pathway, Pharmacokinetics/Pharmacodynamics
    Representation of the candidate genes involved in the metabolism of platinum containing drugs.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

No related drugs are available.

Curated Information ?

Publications related to Platinum compounds: 65

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. Pharmacological research. 2016. Pérez-Ramírez Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis. Oncotarget. 2016. Chen Juan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile. European journal of clinical pharmacology. 2016. Pereira Deolinda, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016. Gong Wei-Jing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients. Acta pharmacologica Sinica. 2015. Yin Ji-ye, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Wnt signaling pathway pharmacogenetics in non-small cell lung cancer. The pharmacogenomics journal. 2014. Stewart D J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer letters. 2014. Sullivan Ivana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clinical pharmacology and therapeutics. 2014. Pu X, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. Li Xiang-Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response. Clinical and experimental pharmacology & physiology. 2014. Wang Ying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis. Journal of gastroenterology and hepatology. 2014. Wu Hongju, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics. 2014. Khrunin Andrey V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy. Genetics and molecular research : GMR. 2014. Zhang L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer. Molecular carcinogenesis. 2013. Liu Li, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma. PloS one. 2014. Jin Hekun, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-Fluorouracil combination chemotherapy. PloS one. 2014. Geng Ruixuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. Pharmacogenetics and genomics. 2013. Rumiato Enrica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Understanding platinum-induced ototoxicity. Trends in pharmacological sciences. 2013. Langer Thorsten, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
XBP1 promoter polymorphism modulates platinum-based chemotherapy gastrointestinal toxicity for advanced non-small cell lung cancer patients. Lung cancer (Amsterdam, Netherlands). 2013. Peng J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. PloS one. 2013. Shen Xiao-yong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment. Chest. 2012. Qian Ji, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for GSTT1. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An intronic polymorphism in GRP78 improves chemotherapeutic prediction in non-small cell lung cancer. Chest. 2012. Zhu Xiao, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy. Pharmacogenomics. 2012. Yan Li, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenetics and genomics. 2012. Er¿ulj Nina, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics. 2012. Khrunin Andrey, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and genomics. 2011. Jamieson David, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011. Giovannetti Elisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PloS one. 2012. Yin Ji-Ye, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics. 2011. Tzvetkov Mladen V, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011. Ryu Jeong-Seon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. The pharmacogenomics journal. 2011. Wheeler H E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. The pharmacogenomics journal. 2011. Biason P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Vaezi Alec, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncology reports. 2011. Kolesar Jill M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics. 2011. Lamas Maria J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
THYMIDYLATE SYNTHASE AND EXCISION REPAIR-CROSS-COMPLEMENTING GROUP-1 AS PREDICTORS OF RESPONSIVENESS IN MESOTHELIOMA PATIENTS TREATED WITH PEMETREXED-CARBOPLATIN. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Zucali Paolo Andrea, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenetics and genomics. 2011. Huang Ming-Yii, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. The Journal of pathology. 2011. Lee Soo-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients. Cancer research. 2010. Wu Chen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC19A1 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Yee Sook Wah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glutathione S-transferase polymorphisms in osteosarcoma patients. Pharmacogenetics and genomics. 2010. Salinas-Souza Carolina, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. McLeod Howard L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Molecular cancer therapeutics. 2010. More Swati S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010. Moyer Ann M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. The pharmacogenomics journal. 2010. Khrunin A V, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. British journal of clinical pharmacology. 2010. Etienne-Grimaldi Marie-Christine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of taxane/platinum therapy in ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009. Marsh Sharon. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. Journal of hematology & oncology. 2010. Dong Song, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. The pharmacogenomics journal. 2009. Caronia D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Choi Ji-Yeob, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenetics and genomics. 2009. Bradbury Penelope A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Advanced drug delivery reviews. 2009. Marsh Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecologic oncology. 2009. Kim Hee Seung, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clinical lung cancer. 2009. Kalikaki Aristea, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer chemotherapy and pharmacology. 2008. Font Albert, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nature genetics. 2008. Fagerholm Rainer, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008. Tibaldi Carmelo, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Ruzzo Annamaria, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecologic oncology. 2006. Chung Hyun Hoon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006. Booton Richard, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Lecomte Thierry, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. British journal of cancer. 2004. Stoehlmacher J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Molecular pharmacology. 2001. Siegel D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999. Siegel D, et al. PubMed

Clinical Trials

These are trials that mention Platinum compounds and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.